Embolotherapies used in the treatment of hepatocellular carcinoma (HCC) include bland embolization, conventional transarterial chemoembolization (cTACE) using ethiodol as a carrier, TACE with drug-eluting beads and super absorbent polymer microspheres (DEB-TACE), and selective internal radiation therapy (SIRT). Successfully treated HCC lesions undergo coagulation necrosis, and appear as nonenhancing hypoattenuating or hypointense lesions in the embolized region on computed tomography (CT) and magnetic resonance.
new cases in 2013 [2] . Definitive treatment of HCC includes surgical resection or liver transplantation. However, several minimally invasive locoregional therapies have proven to successfully treat HCC, including radiofrequency ablation, transarterial chemoembolization (TACE), and selective internal radiation therapy (SIRT). Treatment decisions depend on many factors and can be variable between institutions, and the Barcelona Clinic Liver Cancer staging classification and treatment algorithm is frequently used to direct therapy based on tumour stage, liver functional status, physical status, and cancer-related symptoms [3] .
Follow-up imaging is essential in assessing treatment response after locoregional therapies and determining if further therapy is required. Response to treatment has classically been measured by change in tumour size and number, according to the World Health Organization (WHO) and Response Evaluation Criteria in Solid Tumours (RECIST) guidelines. The WHO criteria published in 1979 measures tumours in 2 dimensionsdthe longest diameter is multiplied by the greatest perpendicular diameter [4] . The RECIST guideline published in 2000 (version 1.0) includes unidimensional measurement of tumours by their longest diameter in the axial plane [5] , and was initially adopted by regulatory agencies such as the U.S. Food and Drug Administration for drug approval. Disease progression was defined as greater than 20% increase in the sum of diameters of target lesions. The RECIST guideline was revised in 2009 (version 1.1) to include a greater than 5 mm absolute increase, in addition to 20% increase, in the sum of all diameters of target lesions [6] .
The major pitfall of the WHO and RECIST criteria with regards to assessing tumour response are that they do not account for tumour necrosis induced by locoregional embolotherapies such as TACE and SIRT. Since tumour necrosis does not always correlate with corresponding change in tumour size, the effectiveness in locoregional therapies are not properly reflected in the WHO and RECIST guidelines. The European Association for the Study of the Liver recommended measuring the reduction in viable tumour (ie, areas of contrast uptake on the arterial phase) rather than overall tumour size [7] . The modified RECIST (mRECIST) criteria was developed by the American Association of Liver Disease for evaluation of HCC specifically, where only the viable portion of the tumour is included as the target lesion [8] . Table 1 compares the differences in response definitions between WHO, RECIST, RECIST 1.1, and mRECIST.
Multiple imaging modalities may be used to determine HCC tumour viability after locoregional embolotherapies, particularly computed tomography (CT) and magnetic resonance imaging (MRI). The aim of this article is to discuss the imaging appearances and pitfalls of HCCs following embolotherapies on CT and MRI.
Imaging Protocols

Computed Tomography
Multidetector CT (MDCT) is a widely utilised imaging modality following locoregional embolotherapy, allowing for acquisition of contiguous slices in multiple phases following intravenous contrast administration [8] . At our institution, MDCT is performed either on a 64-slice scanner (Siemens SOMATOM Sensation Cardiac, Siemens Healthcare, Erlangen, Germany), 320-slice scanner (Toshiba Aquilion 1, Toshiba Medical Systems, Tochigi, Japan), or dual-source 128-slice scanner (Siemens SOMA-TOM Definition FLASH, Siemens Healthcare, Erlangen, Table 1 Comparison of tumour response criteria among WHO guidelines [2] , RECIST 1.0 [3] , RECIST 1.1 [4] , and mRECIST for HCC [8] Germany), with the choice of scanner depending purely on availability with no objective difference in diagnostic ability between scanners. Axial images (3 mm slice thickness with 1.5 mm spacing) were obtained from the level of the diaphragm to iliac crests to ensure complete coverage of the liver using a multiphase protocol, with coronal reformatted images (3 mm slice thickness) subsequently generated. The minimum size of lesions to be detected should be no less than double the slice thickness, otherwise lesion size could be underestimated initially and falsely assessed to have progressed or responded on subsequent exams [5] . A noncontrast examination is acquired 1 month following conventional TACE and 2 weeks following super absorbent polymer microsphere TACE with 5 mm slice thickness and 2.5 mm spacing. Dynamic contrast imaging is performed following injection of 2 mL/kg of iodinated intravenous contrast agent (Optiray 320, Mallinckrodt, St. Louis, MO) to a maximum volume of 150 mL, injected at a rate of 4 mL/s followed with a saline bolus of 20 mL. Arterial phase imaging is obtained at 35 seconds from the time of contrast injection, portal venous phase at 70 seconds, and a delayed phase at 3 minutes with a bolus tracking technique. A late arterial phase is obtained to allow for some portal vein enhancement rather than an early arterial angiographic phase. The portal venous phase is acquired when liver parenchyma is homogeneously enhancing with almost equal enhancement of both portal veins and hepatic veins. A 3-minute delayed phase is acquired to identify any evidence of lesion wash out not seen on the portal venous phase.
CTs are typically performed at 1-, 3-, and 6-month intervals after treatment. However, the follow-up interval may be altered if there is evidence of inadequate treatment or new lesions detected, with repeat imaging recommended at shorter interval [9] .
Magnetic Resonance Imaging
MRI is a well-established imaging modality used to detect and characterize focal liver lesions in both cirrhotic and noncirrhotic patients. At our institution, MRI is not routinely used to follow patients who have undergone locoregional embolotherapy, but rather for indeterminate findings encountered on follow-up CT imaging that need further characterization, patients with iodine-based contrast allergies or clinical findings that are discordant with imaging appearances (e.g., alpha-fetoprotein levels). These cases are discussed in a multidisciplinary clinical forum prior to further management.
MR abdominal imaging is performed on a 1.5-T magnet (Siemens MAGNETOM Aera, Siemens Healthcare, Erlangen, Germany). Axial gradient echo in-and out-of-phase T1-weighted (T1W) and axial and coronal T2-weighted (T2W) fast spin echo (FSE) sequences are obtained with a T2W fat saturated sequence (BLADE, Siemens Healthcare, Erlangen, Germany). Diffusion-weighted images (B values of 50, 500, and 1000) and apparent diffusion coefficient (ADC) maps are also obtained prior to the administration of contrast agents.
A gadolinium-based contrast agent is used for dynamic contrast study with 3D T1W gradient-echo volumetric interpolated breath-hold examination (VIBE, Siemens Healthcare, Erlangen, Germany) sequences. Hepatobiliary contrast agents such as gadobenate dimeglumine (MultiHance, Bracco, Singen, Germany) and gadoxetate disodium (Primovist, Bayer, Leverkusen, Germany) are routinely used, which demonstrate 5% and 50% biliary excretion in patients with normal hepatic function, respectively, and the hepatobiliary phase obtained 1-2 hours and 10e20 minutes post injection, respectively.
Embolotherapies
Bland Embolization
Bland embolization, also known as transcatheter arterial embolization (TAE), induces tumour cell death by occluding the tumour-feeding arteries with particles leading to severe tissue hypoxia triggering apoptosis. Embolic agents vary widely in size and characteristics and include: absorbable gelatin (Gelfoam, Pfizer, New York City, NY), trisacryl (Embospheres, Merit Medical, South Jordan, UT), polyvinyl alcohol (various manufacturers in both asteroidal and spherical form), and acryl amine polymers (QuadraSphere, Merit Medical, South Jordan, UT). The use of larger particles causes proximal vessel blockade, which may only induce transient ischemia and inadequate hypoxia to tumour cells, whereas the use of microspheres can achieve terminal arteriole or capillary level vessel occlusion [10] .
The hypoxia caused by bland embolization induces tumour cell death, but may also stimulate neoangiogenesis and apoptosis, which is associated with metastasis and poor outcomes [11] . Bland embolization is commonly not used alone but rather as a complement to drug-carrier based therapies to optimize distribution. However, there is little evidence that TAE is inferior to chemoembolization, and the use of TAE versus chemoembolization is often institution specific [12] . Thus bland embolization can be used as an alternative to chemoembolization or to decrease vascular supply to a tumour prior to surgery, although this is not common practice at our institution.
Computed tomography
Multiphasic imaging is critical to the assessment of therapeutic response and involves identifying areas of necrosis within the treated tumour. Tumour necrosis appears as nonenhancing, low-attenuation areas in place of the previously enhancing target lesion (Figure 1 ). Recurrent or residual tumours demonstrate arterial enhancement with washout of contrast on portal venous or delayed phases [10] . Contrast agents injected during the procedure may be retained within the tumour for up to several days after bland embolization [13] , although most cases do not result in contrast retention.
Baseline post-therapy imaging is typically performed 4e 6 weeks after treatment, with follow-up imaging commonly performed at 3 months for assessing recurrence.
Magnetic resonance imaging
While MRI may be used for post-bland embolization assessment, it is not often required, as MDCT alone is adequate in identifying residual tumours [10] .
Conventional Transarterial Chemoembolization
cTACE involves selective embolization of tumour-feeding arteries and transarterial administration of chemotherapeutic drugs with ethiodized oil acting as a drug-transport agent for the chemotherapeutic agent. The procedure localizes and enhances the effect of the chemotherapeutic agent to the target lesion [14] . The procedure includes the administration of bland embolic following the administration of 100% of the ethiodized oil and chemotherapeutic agent in order to reach terminal stasis in the target vessels. Once a HCC has been exposed to the chemotherapeutic drug and bland embolic, acute ischemic damage occurs in the lesion resulting in coagulation necrosis [15] . Chemotherapeutic agents include doxorubicin, doxorubicin þ cisplatin þ mitomycin c, or cisplatin only. Embolic material may consist of trisacryl microspheres, gelfoam, or polyvinyl alcohol [10] . 
Computed tomography
CT is a standard follow-up imaging technique after cTACE. Treated areas demonstrate high-attenuation ethiodized oil deposition on unenhanced CT [16] , which is utilised postprocedure to assess adequacy of ethiodized oil deposition. The distribution and pattern of accumulation may be predictive of therapeutic response to cTACE, and can be classified into the following types ( Figure 2 ): Type I is homogenous accumulation in and around the tumour and corresponds to the highest nonrecurrence and cumulative survival rate; type II demonstrates defect accumulation within the tumour; type III is heterogeneous accumulation; type IV is only slight or no accumulation in the tumour [17] . Unenhanced CT follow-up is usually reserved for at least 1 month postprocedure to assess ethiodized oil dispersal within treated lesions.
Unenhanced CT is used to confirm technical success of cTACE, but alone does not allow complete evaluation of therapeutic response. Direct comparison between pre-and post-treatment imaging is essential to ensure malignant lesions have been appropriately targeted. The addition of contrast is required to assess for presence of residual tumours that may arise outside of ethiodized oil deposition. On contrast-enhanced CT, arterial phase imaging is utilised to identify any residual hyperenhancing mass, while the portal venous and delayed phases assess for washout in any arterially enhancing lesions [15] . Successfully treated lesions with necrotic tissue remain hypoattenuating. Highattenuating retained ethiodized oil may obscure areas of enhancing tumour on arterial phase, thus reducing the sensitivity of CT detection of residual tumour based on arterial enhancement [16] (Figure 3 ). Perilesional hyperenhancement due to physiologic post-treatment inflammatory response may be present, but can be differentiated from inadequately treated tumour by its absence of portal venous washout and is typically circumferential rather than nodular ( Figure 4 ). More recently, dual-energy CT has been used to better detect foci of residual tumour utilising monochromatic imaging at 70 keV [18, 19] .
Arterioportal shunts may develop following chemical or ischemic injury to small intrahepatic arteries and portal veins [20] , resulting in redistributed arterial flow into focal regions of portal venous flow that appear as wedge-shaped or irregular regions of subcapsular arterial enhancement [21] , mimicking recurrent or residual tumour. These regions of benign perfusional changes can be differentiated from tumour in that they become isoattenuating to background liver on portal venous and delayed phases ( Figure 5 ).
Special considerations are required for evaluation of nodules treated initially with cTACE and subsequently with radiofrequency ablation. Ablation therapy may disrupt and scatter deposited ethiodized oil from prior cTACE [22] , likely as a result of increased intratumoural pressure during ablation [23] . Ethiodized oil may spill into peritoneal space if the tumour is subcapsular in location [22] .
Magnetic resonance imaging
The appearance of lesions after cTACE can be variable in signal intensity on T1W and T2W images [24] . Tumour necrosis is typically T2 hypointense whereas residual tumours are T2 hyperintense [15] . However, treated lesions with hemorrhage, cystic necrosis, or inflammation can appear T2 hyperintense [25] , mimicking residual tumour. Treated lesions are typically T1 hypointense, but can be T1 hyperintense if proteinaceous fluid or hemorrhage is present.
The advantage of MRI over CT is the absence of beam hardening artifact from residual ethiodized oil and thus better distinction of any residual tumour. The distribution of ethiodized oil can be assessed using T1W in-and out-ofphase sequences. Areas with retained ethiodized oil demonstrate signal dropout on the out-of-phase sequence due to the microfatty composition of ethiodized oil ( Figure 6 ).
As with contrast-enhanced CT, post-cTACE necrotic tissue does not enhance on dynamic MRI (Figure 6 ). Enhancing areas on gadolinium-enhanced dynamic T1W gradient recalled echo pulse sequences may represent residual tumour [24] . Intratumoural high T1 signal intensity on precontrast MR images may obscure assessment of contrast uptake [26] . However, subtraction images can be used to distinguish true tumour enhancement from high T1 signal necrosis (Figure 7 ).
Post-treatment reactive granulation tissue presents as well-circumscribed uniform perilesional enhancement due to increased capillary permeability. This expected finding may mimic or obscure visualization of residual tumour [27] but does not demonstrate washout on portal venous or delayed scans seen with viable tumours [28] (Figure 8) . Alternatively, hepatocyte-specific contrast agents such as gadobenate dimeglumine (Multihance) or gadoxetate disodium (Primovist/Eovist) can be used to demonstrate lack of enhancement in residual tumours in the hepatobiliary phase [28] (Figure 7) . The hepatobiliary phase is also useful for differentiating regions of arterially enhancing arterioportal shunting from residual tumour, where regions of benign perfusional changes will demonstrate normal uptake of the hepatocyte-specific agent equal to background liver [29] (Figure 5 ).
Diffusion-weighted imaging (DWI) is a useful adjunct in the assessment of therapeutic response. In addition to identifying a decrease in tumour size or enhancement, an increase in the apparent diffusion coefficient (ADC) can provide further evidence of tumour necrosis [27] . Treated tumour cells that have undergone necrosis demonstrate increased cell membrane permeability, which allows for increased mobility of water molecules and thus increased ADC (Figure 8) . Conversely, viable residual cancerous cells with intact cell membranes that limit water molecule mobility have lower ADC values (Figure 7 ). Early functional evaluation using DWI and contrast-enhanced MR may provide an earlier determination of response to cTACE compared to change in Figure 5 . Arterioportal shunt following conventional transarterial chemoembolization (TACE). Arterial (A) and delayed (B) phase computed tomography 6 months following left TACE for treatment of a segment II hepatocellular carcinoma (HCC) lesion (not shown) demonstrates subcapsular wedge-shaped arterial enhancement in segment II/III (arrow) with no delayed washout. The corresponding area on magnetic resonance performed shortly after also demonstrates arterial enhancement with no portal venous washout on the postcontrast T1-weighted volumetric interpolated breath-hold examination arterial (C) and venous (D) phases, and is isointense to background liver parenchyma on the hepatobiliary phase (E), confirming the presence of an arterioportal shunt rather than residual hepatocellular carcinoma (HCC). A subcentimeter hypervascular lesion in segment V/VIII (circle) is also seen on the arterial phase (C), which does not wash out on the venous phase (D) but is hypointense to background liver parenchyma on the hepatobiliary phase (E), indeterminate for HCC given its small size.
size at long-term follow-up [30] . ADC ratio comparing values from baseline to 1 month after TACE is an independent predictor of progression-free survival [31] . The ability to obtain both anatomical and functional information on MR makes this modality ideal for early imaging follow-up [27] .
TACE With Drug-Eluting Beads
TACE with drug-eluting beads and super absorbent polymer microspheres (DEB-TACE) is an alternative to conventional TACE therapy. Drug-eluting beads are Once deposited into the tumour, doxorubicin is eluted, prolonging tumour exposure to the drug while limiting systemic exposure and toxicity [32] . Overall, this method enhances tumour drug delivery and demonstrates reduced peak plasma doxorubicin concentration and drug-related side effects compared to conventional TACE [14] . DEB-TACE has been shown to be noninferior to conventional TACE [33] ; however, the Prospective Randomized Study of Doxorubicin in the Treatment of Hepatocellular Carcinoma by Drug-Eluting Bead Embolization (PRECISION) V study demonstrated significantly lower doxorubicin-related events using DEB-TACE compared to conventional TACE. Because of the lower rates of side effects, together with improved objective response and disease control in patients with advanced disease (Child Pugh B, bilobar disease, and recurrent disease), DEB-TACE is reserved for patient with advance disease and increased comorbidities including renal and cardiac dysfunction in our institution.
Computed tomography
Unlike conventional TACE, there are no residual hyperattenuating areas on CT because ethiodized oil is not used ( Figure 9 ). There may be retained iodine contrast agent present post procedure, which can serve as an appropriate surrogate for particle deposition, but this will be resolved after several days [10] .
A hyperemic rim is also seen posteDEB-TACE as a result of postinflammatory changes and should not to be confused with residual tumour on immediate follow-up imaging (ie, at 1 month) ( Figure 10 ). Progression of Figure 11 . Computed tomography (CT) and magnetic resonance (MR) appearances of lesion successfully treated by transarterial chemoembolization with drug-eluting beads and super absorbent polymer microspheres (DEB-TACE). (A) CT in arterial phase demonstrates a hypervascular lesion in segment V (white arrow) that washes out on portal venous phase, in keeping with hepatocellular carcinoma (HCC). (B) Six months after DEB-TACE, the lesion has retracted and is hypoenhancing (black arrow), indicating successful treatment of the segment V lesion. However, there is new wedge-shaped irregular arterial enhancement in segment VI (white arrowhead) that persists on delayed phases, indeterminate for HCC. Follow-up MR was recommended to further characterize the new abnormalities. On MR performed 9 months following DEB-TACE, the treated segment V lesion (black arrowhead) is hypointense on T1-weighted (T1W) (C) and T2-weighted (D) sequences, and does not enhance on dynamic post-Primovist T1W fast spin gradient recalled echo sequences on arterial (E) and hepatobiliary (F) phases, in keeping with a successfully treated lesion. However, new lesions suspicious for HCC are present in segment VI as indicated by a new hypointense lesion (circle) on the hepatobiliary phase (G) that subtly enhances on the arterial phase subtraction image (H). enhancement on subsequent follow-up imaging (ie, 3e 6 months) is suggestive of recurrent or residual tumour. The pattern of enhancement is predictive of recurrent or residual tumour: a complete thin ring of peripheral enhancement is more likely to be benign rather than an incomplete ring or nodular enhancement [34] . CT has been shown to have excellent correlation to histological specimens following DEB-TACE [35] .
Magnetic resonance imaging
MRI is an alternative to follow-up treatment with DEB-TACE. Tumour necrosis following DEB-TACE demonstrates similar MR characteristics as lesions treated with conventional TACE (Figure 11 ). Careful comparison with preprocedure imaging is required to determine treatment response.
Selective Internal Radiation Therapy
SIRT involves intratumoural arterial placement of microspheres (TheraSphere, BTG Medical, Framingham, England; SIR-Spheres, SIRTeX Medical, Sydney, Australia) containing radioactive particles such as yttrium-90 (Y90). The Y90 particles emit high-energy beta rays with maximum penetration of approximately 1 cm, delivering intense radiotherapy localized to tumourous tissue [36] . It has emerged as a treatment alternative to TACE, particularly in patients with portal venous tumour extension, and has been shown to result in longer time to disease progression and lower toxicity [37] .
SIRT may be used in the treatment of intermediate and selected categories of advanced HCC. It is ideal for patients with no vascular invasion or extrahepatic disease, but this is not an absolute contraindication to treatment of these forms of tumour spread. SIRT can be considered in HCC with vascular invasion, where other locoregional therapies are contraindicated or have limited therapeutic value [38] .
Selected candidates for SIRT require mesenteric angiography prior to treatment for technique planning and assessment of gastrointestinal flow [39] . Evaluation of hepatic and visceral vasculature with high resolution CT angiography allows identification of extrahepatic arterial variants that may require prophylactic embolization [40] . Because direct arteriovenous shunting is characteristic of HCC, pretreatment angiography is also used to look for pulmonary shunting. If identified, the amount of shunting is calculated to determine amount of pulmonary radiation exposure, and if more than 30 Gy is absorbed, then radioembolization is contraindicated [36] . Evidence of uncorrectable flow to the gastrointestinal tract due to variant anatomy or significant extra-hepatic disease with a life expectancy of less than 3 months are also exclusions for SIRT [40] . Other requirements for SIRT include noncompromised pulmonary function, ECOG stage 0e2, ability to undergo pretreatment angiography, and adequate hematologic, renal and liver function [40] .
CT and MRI
As with other embolotherapies, treatment response from SIRT is measured by amount of tumour size reduction and degree of coagulation necrosis. Areas of arterial enhancement and subsequent washout on follow-up CT may indicate residual viable tumour and will require additional treatment.
Thin peripheral rim enhancement may be seen secondary to preferential blood flow to the tumour periphery due to radiation exposure from the microspheres lodged into the arterioles [40] . In post-SIRT imaging, rim enhancement is typically a benign finding that may appear within 22e 181 days of treatment, and persist for 25e252 days [41] ( Figure 12) .
As previously discussed, DWI is a valuable technique for functional assessment of therapeutic response. Increased water mobility from compromised cell membrane integrity indicates necrotic tissue and aids in differentiating areas of reactive oedema from residual tumour ( Figure 13 ). DWI is particularly useful during the early follow-up period when a measurable change in tumour size may not be present. Tumour response has been reported to occur as early as approximately 42 days after SIRT therapy with DWI [42] . A 30% increase in ADC values at 30 days following SIRT therapy is predictive of tumour response and prolonged survival in infiltrative HCC with portal vein thrombosis [43] .
Perilesional and perivascular oedema are benign findings that occur after therapy due to an inflammatory reaction to the radiation. This may cause interval enlargement of the lesion that can be misinterpreted as disease progression [40] . The liver parenchyma surrounding the areas of Y90 microsphere distribution may show changes of perivascular oedema that can mimic infiltrative disease [40] . However, this phenomenon is transient and resolves after 3e6 months [44] . SIRT can also result in segmental and geographic liver oedema ( Figure 14) and peribiliary necrosis.
Geographic hyperenhancement in the distribution of the treated segment or lobe is a benign phenomenon but may mimic progressive infiltrative tumour [44] . Local hepatic injury and fibrosis secondary to radiation effect can result in atrophy of the treated liver lobe [45] (Figure 15) , with diversion of circulation and increase in portal venous blood flow to the untreated liver lobe [44] , resulting in compensatory hypertrophy [40] .
Other findings related to radioembolization include capsular retraction secondary to necrosis distorting tumour margins, perihepatic fluid, and pleural effusion resulting from radiation exposure to adjacent structures such as the Glisson capsule and right pleural space ( Figure 14 ) [40] .
Complications
Complications of locoregional embolotherapies that can be seen on follow-up imaging relate to nontarget embolization of other visceral organs. Inadvertent embolization of the cystic artery may result in cholecystitis presenting as pericholecystic fluid and gallbladder mural thickening with irregular enhancement, while embolization of the pancreaticoduodenal branches of the gastroduodenal artery may result in pancreatitis [46] . Hepatic parenchymal infarction may also occur due to reduction in arterial and portal perfusion from embolic material [20] ( Figure 16 ). Mechanical vascular injury to the hepatic artery can lead to arterial spasm, inflammatory constriction or, in severe cases, occlusion resulting in hepatic infarction.
In addition to nontarget embolization, chemotherapyrelated complications may occur following cTACE or DEB-TACE. Inadvertent chemoembolization of the gastroduodenal artery can result in chemotherapy-induced gastrointestinal mucosal ulceration and perforation, which is usually prevented by preprocedural embolization with metallic coiling. Chemoembolization of the cystic artery may result in chemical cholecystitis, and protective prophylactic embolization of the cystic artery may be considered prior to TACE. Extrahepatic collaterals such as the inferior phrenic artery may be chemoembolized, resulting in pleural inflammation and effusion [47] . Biliary strictures ( Figure 17 ) and bilomas ( Figure 18 ) may form due to ischemic injury to the peribiliary plexus that are supplied by hepatic artery branches [47] , causing damage to small bile ducts. Hepatic abscesses may also occur either due to infection introduced during the procedure, infection superimposed on embolized necrotic parenchyma, or immunosuppressant effect of chemotherapeutic agent [48] (Figure 19) .
A number of radiation-related complications may occur following SIRT. Biliary dyskinesia and clinical or subclinical radiation cholecystitis may occur from nontarget embolization of Y90 microspheres entering the cystic duct [40] , and prophylactic cystic artery embolization is considered as with TACE to minimize exposure of gallbladder to radiotherapeutic agents [49] . Radiation-induced liver disease can occur when normal hepatic parenchyma is exposed to excess radiation doses causing a deterioration in liver function [44] . Radiation pneumonitis may occur due to tumour-induced arteriovenous pulmonary shunting or with radiation doses greater than 30 Gy, resulting in prolonged radiation exposure to lung parenchyma and may eventually lead to pulmonary fibrosis [50] , but this a rare occurrence.
Conclusion
CT and MRI are essential in the follow up of HCC postlocoregional embolotherapy to assess tumour response both quantitatively and qualitatively. Multiphase contrast-enhanced CT obtained in the arterial, portal venous, and delayed phases is the workhorse of postembolotherapy imaging. Special consideration should be given to patients receiving their first follow-up CT following conventional TACE, where a noncontrast study should be performed first that will serve as a baseline for ethiodized oil distribution. Physiologic inflammatory enhancement following cTACE, DEB-TACE, and SIRT may mimic, but should not be mistaken for, residual or recurrent disease. MR is useful in following patients with indeterminate findings on CT, particularly with dynamic contrast-enhanced T1 sequences with subtraction using hepatocyte-specific gadolinium contrast agents and diffusion-weighted sequences that will highlight any residual tumour. Familiarity with imaging pitfalls of both CT and MR postembolotherapy can ensure appropriate imaging modalities and techniques are employed and scans are correctly interpreted to distinguish residual from successfully treated HCC lesions.
